The European Commission has granted conditional marketing authorization to Elrexfio (elranatamab) to treat adults with multiple myeloma…
Articles by Margarida Maia, PhD
A study has observed a rise in the number of new cases of myeloma in both men and women…
The first multiple myeloma patient has been dosed in a Phase 1 clinical trial evaluating the safety and efficacy…
Three research projects have been awarded $7 million each from the Multiple Myeloma Research Foundation (MMRF) to develop more…
The U.S. has approved BioLineRx’s Aphexda (motixafortide) in combination with filgrastim (G-CSF) to improve the process of autologous…
Some multiple myeloma cells acquire mutations that allow them to act in disguise and to escape the effects of…
Most patients with hard-to-treat multiple myeloma given NXC-201 — Nexcella’s experimental point-of-care CAR T-cell therapy — as part…
SP-3164, an investigational small molecule protein degrader, showed potential for improved anti-multiple myeloma activity over similar approved compounds. That’s…
The European Commission has approved Pepaxti (melphalan flufenamide, also called melflufen), a medicine by Oncopeptides to be used in…
Oncopeptides received a positive opinion from an arm of the European Medicines Agency (EMA) that is expected to take…